Sigyn Therapeutics (SIGY) Interest Expenses (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Interest Expenses of $13015.0 for Q2 2025, down 88.6% sequentially from $114159.0 in Q1 2025, and down 11.03% YoY from $14628.0 in Q2 2024.
Sigyn Therapeutics (SIGY) Interest Expenses (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Interest Expenses for 10 years, with the latest figure at $13015.0 in Q2 2025.
- Quarterly Interest Expenses fell 11.03% year-over-year to $13015.0 in Q2 2025, while the trailing twelve-month figure through Sep 2025 was $30860.0 (up 185.61% YoY) and the FY2024 annual result came in at $4.0 million, up 30.91% from the prior year.
- Interest Expenses fell to $13015.0 in Q2 2025 per SIGY's latest filing, from $114159.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $114159.0 in Q1 2025 and troughed at -$1678.0 in Q4 2023.
- A 5-year average of $35908.6 and a median of $30800.0 in 2021 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses slumped 103.37% in 2023, then soared 1263.47% in 2024.
- Over 5 years, Interest Expenses stood at $30800.0 in 2021, then soared by 61.63% to $49781.0 in 2022, then slumped by 103.37% to -$1678.0 in 2023, then jumped by 1263.47% to $19523.0 in 2024, then plunged by 33.34% to $13015.0 in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $13015.0, $114159.0, and $19523.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 13,015.00 |
| Jun 30, 2025 | 13,015.00 |
| Mar 31, 2025 | 114,159.00 |
| Mar 31, 2025 | 114,159.00 |
| Dec 31, 2024 | 19,523.00 |
| Dec 31, 2024 | 19,523.00 |
| Sep 30, 2024 | 10,805.00 |
| Sep 30, 2024 | 10,805.00 |
| Jun 30, 2024 | 14,628.00 |
| Jun 30, 2024 | 14,628.00 |
| Mar 31, 2024 | 54,225.00 |
| Mar 31, 2024 | 54,225.00 |
| Dec 31, 2023 | -1,678.00 |
| Dec 31, 2023 | -1,678.00 |
| Sep 30, 2023 | 28,317.00 |
| Sep 30, 2023 | 28,317.00 |
| Jun 30, 2023 | 54,224.00 |
| Jun 30, 2023 | 54,224.00 |
| Mar 31, 2023 | 39,180.00 |
| Mar 31, 2023 | 39,180.00 |